Overview
The recent development of several new, non-peptide, orally active angiotensin II receptor antagonists is revolutionizing the treatment of patients with hypertension and various cardiovascular disorders. In this book experts review the current state of angiotensin II antagonists and survey the progress of these diverse applications. Issues relating to angiotensin II and their receptors are examined in relation to their effects on the kidney, non-diabetic renal disease, heart disease, diabetes mellitus, and various other disorders. The combination of AT1 receptor antagonists with other antihypertensive agents is reviewed in depth.
The book contains black-and-white illustrations.
Synopsis
The recent development of several new, non-peptide, orally active angiotensin II receptor antagonists is revolutionizing the treatment of patients with hypertension and various cardiovascular disorders. In this book experts review the current state of angiotensin II antagonists and survey the progress of these diverse applications. Issues relating to angiotensin II and their receptors are examined in relation to their effects on the kidney, non-diabetic renal disease, heart disease, diabetes mellitus, and various other disorders. The combination of AT1 receptor antagonists with other antihypertensive agents is reviewed in depth.
Doody Review Services
Reviewer:John F. Moran, MD(Loyola University Stritch School of Medicine)
Description:This text was written by 48 invited experts in the field of angiotensin II receptor antagonists. It is divided into six sections and contains 25 chapters with material starting from the basics of the angiotensin molecule and its receptor to data on the blockade at the renin angiotensin system. There is a big section on the experiments involving specific systems in the body and a smaller section on the clinical experience with the angiotensin II receptor antagonists.
Purpose:The purpose is to provide current knowledge in a review form on angiotensin receptor antagonists and to survey the progress of the application of these medications. The author's objectives have certainly been met. This is a detailed text.
Audience:This book provides an opportunity to obtain up-to-date information on angiotensin receptor blocker drugs for pharmacologists and physiologists and those working in specific fields of angiotensin receptor.
Features:The first several chapters go over angiotensin receptor blockers and outline the fact that there are several of these receptors such as AT1, ATlb, AT2, AT3, and AT4 that all apparently work through g-protein coupled receptors. The importance of these receptors is recognized by the fact that angiotensin converting enzymes sensitive pathways are not all bought by enzyme blocking drugs. For instance there is the chymase pathway. There is also an important enzyme known as a chymostatin sensitive angiotensin II generating enzymes. The first several chapters also detail some history of this research involving the intravenous peptide Saralasin. There is an interesting chapter on the biochemistry of angiotensin receptor blockers and their development starting with Losartin and Eprosartin and progressing to new drugs currently in development. In addition to the cardiac effects of these drugs, their influence on the sympathetic and central nervous system including the brain and the kidney are detailed.
Assessment:This is a worthwhile addition to the medical literature because it provides an extensive review of material on the angiotensin receptors with well-written chapters that are extremely well referenced. Each chapter has between 100-200 references. This allows all students interested in the field to look up some of the original material. Although there is much clinical data already published, many more interesting studies are currently in progress which should add much to our information about these drugs and their usefulness in treating patients with cardiovascular disease.
Editorials
From The Critics
Reviewer: John F. Moran, MD(Loyola University Stritch School of Medicine)Description: This text was written by 48 invited experts in the field of angiotensin II receptor antagonists. It is divided into six sections and contains 25 chapters with material starting from the basics of the angiotensin molecule and its receptor to data on the blockade at the renin angiotensin system. There is a big section on the experiments involving specific systems in the body and a smaller section on the clinical experience with the angiotensin II receptor antagonists.
Purpose: The purpose is to provide current knowledge in a review form on angiotensin receptor antagonists and to survey the progress of the application of these medications. The author's objectives have certainly been met. This is a detailed text.
Audience: This book provides an opportunity to obtain up-to-date information on angiotensin receptor blocker drugs for pharmacologists and physiologists and those working in specific fields of angiotensin receptor.
Features: The first several chapters go over angiotensin receptor blockers and outline the fact that there are several of these receptors such as AT1, ATlb, AT2, AT3, and AT4 that all apparently work through g-protein coupled receptors. The importance of these receptors is recognized by the fact that angiotensin converting enzymes sensitive pathways are not all bought by enzyme blocking drugs. For instance there is the chymase pathway. There is also an important enzyme known as a chymostatin sensitive angiotensin II generating enzymes. The first several chapters also detail some history of this research involving the intravenous peptide Saralasin. There is an interesting chapter on the biochemistry of angiotensin receptor blockers and their development starting with Losartin and Eprosartin and progressing to new drugs currently in development. In addition to the cardiac effects of these drugs, their influence on the sympathetic and central nervous system including the brain and the kidney are detailed.
Assessment: This is a worthwhile addition to the medical literature because it provides an extensive review of material on the angiotensin receptors with well-written chapters that are extremely well referenced. Each chapter has between 100-200 references. This allows all students interested in the field to look up some of the original material. Although there is much clinical data already published, many more interesting studies are currently in progress which should add much to our information about these drugs and their usefulness in treating patients with cardiovascular disease.
Booknews
Reviews current knowledge of angiotensin II (Ang II) antagonists and surveys the progress of their diverse applications. Section I examines fundamental issues including species variation in the renin- angiotensin system, and signalling and cellular effects of angiotensin. Section II looks at aspects of the blockade of the renin- angiotensin system, with an account of the development of and early experience with Ang II antagonists. Section III reports on experimental studies of the effects of Ang II and AT1 receptor blockade. Sections IV and V discuss clinical experience and ongoing trials with AT1 receptor antagonists. A conclusion looks at unanswered questions. Epstein teaches medicine at the University of Miami School of Medicine. Brunner teaches medicine at Lausanne University. Annotation c. Book News, Inc., Portland, OR (booknews.com)3 Stars from Doody